ID   DDR2_HUMAN              Reviewed;         855 AA.
AC   Q16832; Q7Z730;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 174.
DE   RecName: Full=Discoidin domain-containing receptor 2;
DE            Short=Discoidin domain receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=CD167 antigen-like family member B;
DE   AltName: Full=Discoidin domain-containing receptor tyrosine kinase 2;
DE   AltName: Full=Neurotrophic tyrosine kinase, receptor-related 3;
DE   AltName: Full=Receptor protein-tyrosine kinase TKT;
DE   AltName: Full=Tyrosine-protein kinase TYRO10;
DE   AltName: CD_antigen=CD167b;
DE   Flags: Precursor;
GN   Name=DDR2; Synonyms=NTRKR3, TKT, TYRO10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Heart, and Thymus;
RX   PubMed=8247548;
RA   Karn T., Holtrich U., Braeuninger A., Boehme B., Wolf G.,
RA   Ruebsamen-Waigmann H., Strebhardt K.;
RT   "Structure, expression and chromosomal mapping of TKT from man and
RT   mouse: a new subclass of receptor tyrosine kinases with a factor VIII-
RT   like domain.";
RL   Oncogene 8:3433-3440(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hair follicle dermal papilla, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION AS COLLAGEN RECEPTOR AND IN UP-REGULATION OF MMP1,
RP   PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9659899; DOI=10.1016/S1097-2765(00)80003-9;
RA   Vogel W., Gish G.D., Alves F., Pawson T.;
RT   "The discoidin domain receptor tyrosine kinases are activated by
RT   collagen.";
RL   Mol. Cell 1:13-23(1997).
RN   [7]
RP   FUNCTION IN REGULATION OF MMP1 AND MMP2, PHOSPHORYLATION AT TYR-736;
RP   TYR-740 AND TYR-741, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   INTERACTION WITH SHC1, AND MUTAGENESIS OF LYS-608; TYR-736; TYR-740
RP   AND TYR-741.
RX   PubMed=16186108; DOI=10.1074/jbc.M506921200;
RA   Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
RT   "Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
RT   stimulates intramolecular autophosphorylation and Shc signaling
RT   complex formation.";
RL   J. Biol. Chem. 280:39058-39066(2005).
RN   [8]
RP   FUNCTION AS COLLAGEN RECEPTOR, AND PHOSPHORYLATION.
RX   PubMed=16186104; DOI=10.1074/jbc.M508226200;
RA   Wall S.J., Werner E., Werb Z., DeClerck Y.A.;
RT   "Discoidin domain receptor 2 mediates tumor cell cycle arrest induced
RT   by fibrillar collagen.";
RL   J. Biol. Chem. 280:40187-40194(2005).
RN   [9]
RP   FUNCTION IN UP-REGULATION OF MMP13, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17665456; DOI=10.1002/art.22761;
RA   Xu L., Peng H., Glasson S., Lee P.L., Hu K., Ijiri K., Olsen B.R.,
RA   Goldring M.B., Li Y.;
RT   "Increased expression of the collagen receptor discoidin domain
RT   receptor 2 in articular cartilage as a key event in the pathogenesis
RT   of osteoarthritis.";
RL   Arthritis Rheum. 56:2663-2673(2007).
RN   [10]
RP   FUNCTION AS COLLAGEN RECEPTOR, SUBCELLULAR LOCATION, PHOSPHORYLATION,
RP   AND SUBUNIT.
RX   PubMed=18201965; DOI=10.1074/jbc.M709290200;
RA   Konitsiotis A.D., Raynal N., Bihan D., Hohenester E., Farndale R.W.,
RA   Leitinger B.;
RT   "Characterization of high affinity binding motifs for the discoidin
RT   domain receptor DDR2 in collagen.";
RL   J. Biol. Chem. 283:6861-6868(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION VIA ACTIVATION OF RUNX2,
RP   INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=20564243; DOI=10.1002/jbmr.159;
RA   Lin K.L., Chou C.H., Hsieh S.C., Hwa S.Y., Lee M.T., Wang F.F.;
RT   "Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic
RT   differentiation through p38 MAPK-mediated Runx2 activation.";
RL   J. Bone Miner. Res. 25:2489-2503(2010).
RN   [14]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION AND CHONDROCYTE MATURATION VIA
RP   ACTIVATION OF RUNX2.
RX   PubMed=20734453; DOI=10.1002/jbmr.225;
RA   Zhang Y., Su J., Yu J., Bu X., Ren T., Liu X., Yao L.;
RT   "An essential role of discoidin domain receptor 2 (DDR2) in osteoblast
RT   differentiation and chondrocyte maturation via modulation of Runx2
RT   activation.";
RL   J. Bone Miner. Res. 26:604-617(2011).
RN   [15]
RP   REVIEW.
RX   PubMed=16626936; DOI=10.1016/j.cellsig.2006.02.012;
RA   Vogel W.F., Abdulhussein R., Ford C.E.;
RT   "Sensing extracellular matrix: an update on discoidin domain receptor
RT   function.";
RL   Cell. Signal. 18:1108-1116(2006).
RN   [16]
RP   REVIEW.
RX   PubMed=21568710; DOI=10.1146/annurev-cellbio-092910-154013;
RA   Leitinger B.;
RT   "Transmembrane collagen receptors.";
RL   Annu. Rev. Cell Dev. Biol. 27:265-290(2011).
RN   [17]
RP   STRUCTURE BY NMR OF 22-186, INTERACTION WITH COLLAGEN, AND DISULFIDE
RP   BONDS.
RX   PubMed=17703188; DOI=10.1038/sj.emboj.7601833;
RA   Ichikawa O., Osawa M., Nishida N., Goshima N., Nomura N., Shimada I.;
RT   "Structural basis of the collagen-binding mode of discoidin domain
RT   receptor 2.";
RL   EMBO J. 26:4168-4176(2007).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 26-190 IN COMPLEX WITH
RP   COLLAGEN PEPTIDE, DISULFIDE BONDS, MUTAGENESIS OF TRP-52, FUNCTION IN
RP   COLLAGEN BINDING, CATALYTIC ACTIVITY, AND PHOSPHORYLATION.
RX   PubMed=20004161; DOI=10.1016/j.str.2009.10.012;
RA   Carafoli F., Bihan D., Stathopoulos S., Konitsiotis A.D.,
RA   Kvansakul M., Farndale R.W., Leitinger B., Hohenester E.;
RT   "Crystallographic insight into collagen recognition by discoidin
RT   domain receptor 2.";
RL   Structure 17:1573-1581(2009).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-105.
RX   PubMed=16140923; DOI=10.1158/0008-5472.CAN-05-1855;
RA   Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G.,
RA   Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R.,
RA   Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R.,
RA   Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A.,
RA   West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M.,
RA   Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B.,
RA   Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F.,
RA   Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R.,
RA   Futreal P.A.;
RT   "Somatic mutations of the protein kinase gene family in human lung
RT   cancer.";
RL   Cancer Res. 65:7591-7595(2005).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-105; ILE-441; CYS-478 AND PHE-543.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [21]
RP   VARIANTS SEMD-SL ILE-713; ARG-726 AND CYS-752.
RX   PubMed=19110212; DOI=10.1016/j.ajhg.2008.12.004;
RA   Bargal R., Cormier-Daire V., Ben-Neriah Z., Le Merrer M., Sosna J.,
RA   Melki J., Zangen D.H., Smithson S.F., Borochowitz Z., Belostotsky R.,
RA   Raas-Rothschild A.;
RT   "Mutations in DDR2 gene cause SMED with short limbs and abnormal
RT   calcifications.";
RL   Am. J. Hum. Genet. 84:80-84(2009).
RN   [22]
RP   VARIANT SEMD-SL LYS-113, CHARACTERIZATION OF VARIANTS SEMD-SL LYS-113;
RP   ILE-713; ARG-726 AND CYS-752, MUTAGENESIS OF TRP-52, GLYCOSYLATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=20223752; DOI=10.1093/hmg/ddq103;
RA   Ali B.R., Xu H., Akawi N.A., John A., Karuvantevida N.S., Langer R.,
RA   Al-Gazali L., Leitinger B.;
RT   "Trafficking defects and loss of ligand binding are the underlying
RT   causes of all reported DDR2 missense mutations found in SMED-SL
RT   patients.";
RL   Hum. Mol. Genet. 19:2239-2250(2010).
RN   [23]
RP   VARIANT SEMD-SL TRP-124.
RX   PubMed=26463668; DOI=10.1002/ajmg.a.37426;
RA   Mansouri M., Kayserili H., Elalaoui S.C., Nishimura G., Iida A.,
RA   Lyahyai J., Miyake N., Matsumoto N., Sefiani A., Ikegawa S.;
RT   "Novel DDR2 mutation identified by whole exome sequencing in a
RT   Moroccan patient with spondylo-meta-epiphyseal dysplasia, short limb-
RT   abnormal calcification type.";
RL   Am. J. Med. Genet. A 170:460-465(2016).
CC   -!- FUNCTION: Tyrosine kinase that functions as cell surface receptor
CC       for fibrillar collagen and regulates cell differentiation,
CC       remodeling of the extracellular matrix, cell migration and cell
CC       proliferation. Required for normal bone development. Regulates
CC       osteoblast differentiation and chondrocyte maturation via a
CC       signaling pathway that involves MAP kinases and leads to the
CC       activation of the transcription factor RUNX2. Regulates remodeling
CC       of the extracellular matrix by up-regulation of the collagenases
CC       MMP1, MMP2 and MMP13, and thereby facilitates cell migration and
CC       tumor cell invasion. Promotes fibroblast migration and
CC       proliferation, and thereby contributes to cutaneous wound healing.
CC       {ECO:0000269|PubMed:16186104, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20004161, ECO:0000269|PubMed:20564243,
CC       ECO:0000269|PubMed:20734453, ECO:0000269|PubMed:9659899}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:20004161}.
CC   -!- ENZYME REGULATION: Present in an inactive state in the absence of
CC       collagen binding and phosphorylation by SRC. Tyrosine
CC       phosphorylation enhances the affinity for ATP and the catalytic
CC       activity. {ECO:0000269|PubMed:16186108}.
CC   -!- SUBUNIT: Binds hydroxyproline-rich sequence motifs in fibrillar,
CC       glycosylated collagen, such as the GQOGVMGFO motif, where O stands
CC       for hydroxyproline. Interacts with SRC. Interacts (tyrosine
CC       phosphorylated) with SHC1. {ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:17703188, ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20004161}.
CC   -!- INTERACTION:
CC       P13942:COL11A2; NbExp=2; IntAct=EBI-1381484, EBI-2515504;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1381484, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}.
CC   -!- TISSUE SPECIFICITY: Detected in osteocytes, osteoblastic cells in
CC       subchondral bone, bone lining cells, tibia and cartilage (at
CC       protein level). Detected at high levels in heart and lung, and at
CC       low levels in brain, placenta, liver, skeletal muscle, pancreas,
CC       and kidney. {ECO:0000269|PubMed:17665456,
CC       ECO:0000269|PubMed:20564243, ECO:0000269|PubMed:8247548}.
CC   -!- INDUCTION: Up-regulated during osteoblast differentiation (in
CC       vitro). Up-regulated in cartilage from osteoarthritis patients.
CC       {ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:20564243}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20223752}.
CC   -!- PTM: Tyrosine phosphorylated in response to collagen binding.
CC       Phosphorylated by SRC; this is required for activation and
CC       subsequent autophosphorylation on additional tyrosine residues.
CC       {ECO:0000269|PubMed:16186104, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20004161,
CC       ECO:0000269|PubMed:9659899}.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia short limb-hand type
CC       (SEMD-SL) [MIM:271665]: A bone disease characterized by short-
CC       limbed dwarfism, a narrow chest with pectus excavatum,
CC       brachydactyly in the hands and feet, a characteristic craniofacial
CC       appearance and premature calcifications. The radiological findings
CC       are distinctive and comprise short long bones throughout the
CC       skeleton with striking epiphyses that are stippled, flattened and
CC       fragmented and flared, irregular metaphyses. Platyspondyly in the
CC       spine with wide intervertebral spaces is observed and some
CC       vertebral bodies are pear-shaped with central humps, anterior
CC       protrusions and posterior scalloping.
CC       {ECO:0000269|PubMed:19110212, ECO:0000269|PubMed:20223752,
CC       ECO:0000269|PubMed:26463668}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X74764; CAA52777.1; -; mRNA.
DR   EMBL; AK314388; BAG37013.1; -; mRNA.
DR   EMBL; AK095975; BAG53183.1; -; mRNA.
DR   EMBL; AL445197; CAI15941.1; -; Genomic_DNA.
DR   EMBL; CH471067; EAW90713.1; -; Genomic_DNA.
DR   EMBL; BC052998; AAH52998.1; -; mRNA.
DR   CCDS; CCDS1241.1; -.
DR   PIR; S42621; S42621.
DR   RefSeq; NP_001014796.1; NM_001014796.1.
DR   RefSeq; NP_006173.2; NM_006182.2.
DR   RefSeq; XP_006711407.1; XM_006711344.3.
DR   RefSeq; XP_011507888.1; XM_011509586.2.
DR   RefSeq; XP_011507889.1; XM_011509587.2.
DR   UniGene; Hs.275757; -.
DR   UniGene; Hs.593833; -.
DR   PDB; 2WUH; X-ray; 1.60 A; A=26-190.
DR   PDB; 2Z4F; NMR; -; A=26-186.
DR   PDBsum; 2WUH; -.
DR   PDBsum; 2Z4F; -.
DR   ProteinModelPortal; Q16832; -.
DR   SMR; Q16832; -.
DR   BioGrid; 110975; 10.
DR   DIP; DIP-39699N; -.
DR   IntAct; Q16832; 7.
DR   MINT; MINT-233614; -.
DR   STRING; 9606.ENSP00000356898; -.
DR   BindingDB; Q16832; -.
DR   ChEMBL; CHEMBL5122; -.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1844; -.
DR   iPTMnet; Q16832; -.
DR   PhosphoSitePlus; Q16832; -.
DR   SwissPalm; Q16832; -.
DR   BioMuta; DDR2; -.
DR   DMDM; 215273969; -.
DR   EPD; Q16832; -.
DR   MaxQB; Q16832; -.
DR   PaxDb; Q16832; -.
DR   PeptideAtlas; Q16832; -.
DR   PRIDE; Q16832; -.
DR   DNASU; 4921; -.
DR   Ensembl; ENST00000367921; ENSP00000356898; ENSG00000162733.
DR   Ensembl; ENST00000367922; ENSP00000356899; ENSG00000162733.
DR   GeneID; 4921; -.
DR   KEGG; hsa:4921; -.
DR   UCSC; uc001gcg.4; human.
DR   CTD; 4921; -.
DR   DisGeNET; 4921; -.
DR   GeneCards; DDR2; -.
DR   HGNC; HGNC:2731; DDR2.
DR   HPA; HPA070112; -.
DR   MalaCards; DDR2; -.
DR   MIM; 191311; gene.
DR   MIM; 271665; phenotype.
DR   neXtProt; NX_Q16832; -.
DR   OpenTargets; ENSG00000162733; -.
DR   Orphanet; 93358; Spondyloepimetaphyseal dysplasia - short limb - abnormal calcification.
DR   PharmGKB; PA27196; -.
DR   eggNOG; KOG1094; Eukaryota.
DR   eggNOG; ENOG410XQAI; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000043102; -.
DR   HOVERGEN; HBG005461; -.
DR   InParanoid; Q16832; -.
DR   KO; K05125; -.
DR   OMA; FPLGPDY; -.
DR   OrthoDB; EOG091G05Y8; -.
DR   PhylomeDB; Q16832; -.
DR   TreeFam; TF317840; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   SignaLink; Q16832; -.
DR   SIGNOR; Q16832; -.
DR   EvolutionaryTrace; Q16832; -.
DR   GeneWiki; Discoidin_domain-containing_receptor_2; -.
DR   GenomeRNAi; 4921; -.
DR   PRO; PR:Q16832; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000162733; -.
DR   CleanEx; HS_DDR2; -.
DR   CleanEx; HS_TKT; -.
DR   ExpressionAtlas; Q16832; baseline and differential.
DR   Genevisible; Q16832; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031214; P:biomineral tissue development; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0035988; P:chondrocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:UniProtKB.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0003416; P:endochondral bone growth; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; ISS:UniProtKB.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030500; P:regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.120.260; -; 1.
DR   InterPro; IPR034299; DDR2.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF394; PTHR24416:SF394; 1.
DR   Pfam; PF00754; F5_F8_type_C; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00231; FA58C; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01285; FA58C_1; 1.
DR   PROSITE; PS01286; FA58C_2; 1.
DR   PROSITE; PS50022; FA58C_3; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Complete proteome;
KW   Disease mutation; Disulfide bond; Dwarfism; Glycoprotein; Kinase;
KW   Membrane; Nucleotide-binding; Osteogenesis; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    855       Discoidin domain-containing receptor 2.
FT                                /FTId=PRO_0000016746.
FT   TOPO_DOM     22    399       Extracellular. {ECO:0000255}.
FT   TRANSMEM    400    421       Helical. {ECO:0000255}.
FT   TOPO_DOM    422    855       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       30    185       F5/8 type C. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      563    849       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     569    577       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    710    710       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     608    608       ATP. {ECO:0000305}.
FT   MOD_RES     471    471       Phosphotyrosine; by SRC and
FT                                autocatalysis. {ECO:0000250}.
FT   MOD_RES     736    736       Phosphotyrosine; by SRC and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:16186108}.
FT   MOD_RES     740    740       Phosphotyrosine; by SRC and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:16186108}.
FT   MOD_RES     741    741       Phosphotyrosine; by SRC and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:16186108}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    213    213       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    261    261       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    372    372       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     30    185
FT   DISULFID     73    177
FT   VARIANT     105    105       R -> S (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:16140923,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041498.
FT   VARIANT     113    113       E -> K (in SEMD-SL; abolishes collagen
FT                                binding; dbSNP:rs397514747).
FT                                {ECO:0000269|PubMed:20223752}.
FT                                /FTId=VAR_065719.
FT   VARIANT     124    124       R -> W (in SEMD-SL).
FT                                {ECO:0000269|PubMed:26463668}.
FT                                /FTId=VAR_075417.
FT   VARIANT     441    441       M -> I (in dbSNP:rs34722354).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041499.
FT   VARIANT     478    478       R -> C (in dbSNP:rs34869543).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041500.
FT   VARIANT     543    543       V -> F (in dbSNP:rs55973200).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041501.
FT   VARIANT     713    713       T -> I (in SEMD-SL; causes retention in
FT                                an intracellular compartment and thereby
FT                                abolishes signaling in response collagen
FT                                binding; dbSNP:rs121964865).
FT                                {ECO:0000269|PubMed:19110212,
FT                                ECO:0000269|PubMed:20223752}.
FT                                /FTId=VAR_063050.
FT   VARIANT     726    726       I -> R (in SEMD-SL; causes retention in
FT                                an intracellular compartment and thereby
FT                                abolishes signaling in response collagen
FT                                binding; dbSNP:rs121964864).
FT                                {ECO:0000269|PubMed:19110212,
FT                                ECO:0000269|PubMed:20223752}.
FT                                /FTId=VAR_063051.
FT   VARIANT     752    752       R -> C (in SEMD-SL; causes retention in
FT                                an intracellular compartment and thereby
FT                                abolishes signaling in response collagen
FT                                binding; dbSNP:rs121964863).
FT                                {ECO:0000269|PubMed:19110212,
FT                                ECO:0000269|PubMed:20223752}.
FT                                /FTId=VAR_063052.
FT   MUTAGEN      52     52       W->A: Abolishes collagen binding.
FT                                {ECO:0000269|PubMed:20004161,
FT                                ECO:0000269|PubMed:20223752}.
FT   MUTAGEN     608    608       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:16186108}.
FT   MUTAGEN     736    736       Y->F: Reduces autophosphorylation.
FT                                Abolishes phosphorylation by SRC; when
FT                                associated with F-740 and F-741.
FT                                {ECO:0000269|PubMed:16186108}.
FT   MUTAGEN     740    740       Y->F: Promotes autophosphorylation.
FT                                Abolishes phosphorylation by SRC; when
FT                                associated with F-736 and F-741.
FT                                {ECO:0000269|PubMed:16186108}.
FT   MUTAGEN     741    741       Y->F: Reduces autophosphorylation.
FT                                Abolishes phosphorylation by SRC; when
FT                                associated with F-736 and F-740.
FT                                {ECO:0000269|PubMed:16186108}.
FT   CONFLICT    642    642       A -> S (in Ref. 1; CAA52777).
FT                                {ECO:0000305}.
FT   TURN         27     29       {ECO:0000244|PDB:2WUH}.
FT   STRAND       33     35       {ECO:0000244|PDB:2Z4F}.
FT   TURN         36     38       {ECO:0000244|PDB:2WUH}.
FT   STRAND       39     41       {ECO:0000244|PDB:2WUH}.
FT   HELIX        43     45       {ECO:0000244|PDB:2WUH}.
FT   STRAND       46     49       {ECO:0000244|PDB:2WUH}.
FT   HELIX        54     56       {ECO:0000244|PDB:2WUH}.
FT   HELIX        58     60       {ECO:0000244|PDB:2WUH}.
FT   STRAND       70     72       {ECO:0000244|PDB:2WUH}.
FT   STRAND       87    103       {ECO:0000244|PDB:2WUH}.
FT   HELIX       107    109       {ECO:0000244|PDB:2WUH}.
FT   STRAND      116    128       {ECO:0000244|PDB:2WUH}.
FT   STRAND      139    142       {ECO:0000244|PDB:2Z4F}.
FT   STRAND      145    149       {ECO:0000244|PDB:2WUH}.
FT   STRAND      151    169       {ECO:0000244|PDB:2WUH}.
FT   STRAND      171    174       {ECO:0000244|PDB:2Z4F}.
FT   STRAND      178    186       {ECO:0000244|PDB:2WUH}.
SQ   SEQUENCE   855 AA;  96736 MW;  78662021BC53E1A0 CRC64;
     MILIPRMLLV LFLLLPILSS AKAQVNPAIC RYPLGMSGGQ IPDEDITASS QWSESTAAKY
     GRLDSEEGDG AWCPEIPVEP DDLKEFLQID LHTLHFITLV GTQGRHAGGH GIEFAPMYKI
     NYSRDGTRWI SWRNRHGKQV LDGNSNPYDI FLKDLEPPIV ARFVRFIPVT DHSMNVCMRV
     ELYGCVWLDG LVSYNAPAGQ QFVLPGGSII YLNDSVYDGA VGYSMTEGLG QLTDGVSGLD
     DFTQTHEYHV WPGYDYVGWR NESATNGYIE IMFEFDRIRN FTTMKVHCNN MFAKGVKIFK
     EVQCYFRSEA SEWEPNAISF PLVLDDVNPS ARFVTVPLHH RMASAIKCQY HFADTWMMFS
     EITFQSDAAM YNNSEALPTS PMAPTTYDPM LKVDDSNTRI LIGCLVAIIF ILLAIIVIIL
     WRQFWQKMLE KASRRMLDDE MTVSLSLPSD SSMFNNNRSS SPSEQGSNST YDRIFPLRPD
     YQEPSRLIRK LPEFAPGEEE SGCSGVVKPV QPSGPEGVPH YAEADIVNLQ GVTGGNTYSV
     PAVTMDLLSG KDVAVEEFPR KLLTFKEKLG EGQFGEVHLC EVEGMEKFKD KDFALDVSAN
     QPVLVAVKML RADANKNARN DFLKEIKIMS RLKDPNIIHL LAVCITDDPL CMITEYMENG
     DLNQFLSRHE PPNSSSSDVR TVSYTNLKFM ATQIASGMKY LSSLNFVHRD LATRNCLVGK
     NYTIKIADFG MSRNLYSGDY YRIQGRAVLP IRWMSWESIL LGKFTTASDV WAFGVTLWET
     FTFCQEQPYS QLSDEQVIEN TGEFFRDQGR QTYLPQPAIC PDSVYKLMLS CWRRDTKNRP
     SFQEIHLLLL QQGDE
//
